Clinical Trial: Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)

U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07591753) titled 'Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)' on May 11.

Brief Summary: This observational study aims to evaluate the long-term effectiveness and safety of mepolizumab 300 mg/4 weeks in adults with eosinophilic granulomatosis with polyangiitis (EGPA) in the European real-life setting.

The main questions it aims to answer are:

* How effective is mepolizumab 300 mg/4 weeks over long-term follow-up in patients with EGPA?

* How safe is mepolizumab 300 mg/4 weeks during long-term treatment?

* What are the effects of switching mepolizumab dosage from 300 mg/4 weeks to 100 mg/4 weeks, or from 100 m...